BUZZ-Tandem Diabetes Care shares rise due to FDA approval of tubeless insulin pump

November 13 - ** Tandem Diabetes Care (TNDM.O) shares rose 11% to $19.45

** The company stated that the U.S. Food and Drug Administration (FDA) has approved Tandem Mobi as the first and only tubeless automated insulin delivery system that can be worn continuously for up to seven days

** Tandem Mobi now offers both tubeless and tubed insulin delivery options, allowing users flexibility in choosing how to wear their insulin pump

** Plans are in place for a full U.S. launch in the first half of 2027, with related kits and cartridges to be exclusively distributed through pharmacy channels

** Analysts at Piper Sandler commented that this approval is a “positive development,” as investors had previously questioned “why approval took so long and whether there were any issues with the product,” but the approval demonstrates “that is not the case at present”

** Including intraday volatility, the stock has declined 10% year-to-date

(To assist non-native English speakers, Reuters automatically translates its reporting into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters is not liable for any damage or loss arising from the use of automated translation functionality.)